Skip to main content

Table 1 Demographic data of 40 patients with myofascial temporomandibular disorders randomized to treatment with active substance (GRA) or control substance (CTR)

From: Repeated tender point injections of granisetron alleviate chronic myofascial pain - a randomized, controlled, double-blinded trial

 

GRA (n = 20)

CTR (n = 20)

Sex

  

 Female

18

19

 Male

2

1

Age

  

 Mean (SD)

38.3 (15.1)

39.1 (16.1)

 <20

1

1

 20-40

11

12

 >40

8

7

Ethnic origin

  

 Scandinavia

14

15

 Other European countries

2

3

 Africa

1

0

 Asia

2

1

 South America

1

1

Marital status

  

 Never married

8

6

 Married

9

12

 Divorced

3

2

Highest level of education

  

 Elementary school

2

0

 High school

9

10

 College

9

10

  1. GRA Granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), CTR control substance (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden). There were no significant group differences